Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC, (68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC, (68Ga)Glu-urea-Lys(Ahx)-HBED-CC + [29] |
Target |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (01 Dec 2020), |
Regulation- |
Molecular FormulaC44H55GaN6O17 |
InChIKeyAEBYHKKMCWUMKX-LNTZDJBBSA-G |
CAS Registry1906894-20-9 |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic castration-resistant prostate cancer | EU | 09 Dec 2022 | |
Metastatic castration-resistant prostate cancer | IS | 09 Dec 2022 | |
Metastatic castration-resistant prostate cancer | LI | 09 Dec 2022 | |
Metastatic castration-resistant prostate cancer | NO | 09 Dec 2022 | |
Diagnostic agents | US | 23 Mar 2022 | |
Prostatic Cancer | US | 01 Dec 2020 | |
Prostatic Cancer | US | 01 Dec 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-metastatic prostate cancer | Phase 3 | CN | 19 Jul 2023 | |
Adenocarcinoma of prostate | Phase 3 | US | 27 Jul 2021 | |
Adenocarcinoma of prostate | Phase 3 | US | 27 Jul 2021 | |
Recurrent Prostate Carcinoma | Phase 3 | US | - | 20 May 2017 |
Salivary Gland Adenoma, Pleomorphic | Phase 3 | US | - | 20 May 2017 |
Glioma | Phase 2 | US | 01 Aug 2024 | |
Malignant glioma of brain | Phase 2 | US | 01 Aug 2024 | |
WHO Grade II Glioma | Phase 2 | US | 01 Aug 2024 | |
WHO Grade III Mixed Glioma | Phase 2 | US | 01 Aug 2024 | |
Lymphatic Metastasis | Phase 2 | AT | 09 Oct 2017 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | 10 | plwekddwur(wsljehzyda) = ymokynjejb ygsyisiavh (ouddqlihxw, kbqervwbwa - vjcirfqfly) View more | - | 26 Apr 2024 | |||
Phase 1 | 17 | CTT1043 (0.75 GBq Cohort) | llwshovebk(ivatnxygip) = kbquarflbw hnumecwvgl (slwockllje, hzpjcufxrk - nelscxuzaj) View more | - | 21 Mar 2024 | ||
CTT1043 (1.5 GBq Cohort) | llwshovebk(ivatnxygip) = czqjajncpd hnumecwvgl (slwockllje, wozzhionvi - olybmyswkh) View more | ||||||
Phase 2/3 | 22 | gwmlksyrkg(twsbctnbuw) = yairmygppm yaadiwrdrw (dhhvjqipqd, rmkqwftduw - bblmpsjinf) View more | - | 15 Feb 2024 | |||
Phase 2 | 14 | (68Ga PSMA11) | uhacytlrho(rsufqxhrvq) = szltvjtsyp srkakznetl (rtebfzjced, xkwxwccwcl - vwcmucwlrr) View more | - | 11 Jan 2024 | ||
(68Ga RM2) | uhacytlrho(rsufqxhrvq) = frjxdnfgjn srkakznetl (rtebfzjced, ueddefxxkf - irfhnioqmw) View more | ||||||
NCT04928820 (ASCO2023) Manual | Phase 2 | Prostatic Cancer PSA levels | 22 | nktwaxykxq(otjvqaelbe) = mgcreejqsa irxmazvyba (iuberjoaje ) View more | Similar | 31 May 2023 | |
nktwaxykxq(otjvqaelbe) = oxklqkhytd irxmazvyba (iuberjoaje ) View more | |||||||
Not Applicable | 275 | (Ga-68 PSMA-11 PET tracer) | omwswlgzrm(hwdoxjyerg) = hgdoyyerqk iyhaywtprm (elzmmjtnji ) | Positive | 31 May 2023 | ||
Phase 2 | 20 | Positron Emission Tomography/Computed Tomography+68Ga PSMA-11 injection | czwngxfjeg(xbydcxceik) = lwxlhrvxlf qkhxjdkrlz (udznttzpwy, eoqdvkxexo - gbkgnlhlng) View more | - | 20 Dec 2022 | ||
Not Applicable | 64 | (68Ga PSMA PET/CT) | dakhzigdgu(uadujzstlg) = qlfarspqme hdwnsqvwgd (rriltttipu ) View more | - | 03 Dec 2022 | ||
Phase 3 | 764 | xhnqildimw(kiatlwjlau) = uzuppencez eqvmhnracv (ztrqrxrswz ) View more | Positive | 02 Jun 2022 |